Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Purchases 8,375 Shares of Boston Scientific Corporation $BSX

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA boosted its position in Boston Scientific Corporation (NYSE:BSX) by 679.2% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 9,608 shares of the medical equipment provider’s stock after purchasing an additional 8,375 shares during the period. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings in Boston Scientific were worth $984,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Tema Etfs LLC boosted its stake in shares of Boston Scientific by 148.1% in the 3rd quarter. Tema Etfs LLC now owns 42,950 shares of the medical equipment provider’s stock worth $4,193,000 after buying an additional 25,641 shares during the last quarter. Deltec Asset Management LLC lifted its holdings in Boston Scientific by 51.2% during the third quarter. Deltec Asset Management LLC now owns 42,800 shares of the medical equipment provider’s stock worth $4,179,000 after acquiring an additional 14,500 shares during the period. Forum Financial Management LP lifted its holdings in Boston Scientific by 19.6% during the third quarter. Forum Financial Management LP now owns 15,021 shares of the medical equipment provider’s stock worth $1,466,000 after acquiring an additional 2,459 shares during the period. ORG Wealth Partners LLC purchased a new position in Boston Scientific in the third quarter worth $207,000. Finally, Fairfield Financial Advisors LTD grew its stake in Boston Scientific by 97.5% in the 3rd quarter. Fairfield Financial Advisors LTD now owns 5,216 shares of the medical equipment provider’s stock valued at $509,000 after purchasing an additional 2,575 shares during the period. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Down 2.0%

Boston Scientific stock opened at $95.67 on Tuesday. The firm has a 50 day simple moving average of $97.52 and a 200 day simple moving average of $100.67. The company has a current ratio of 1.51, a quick ratio of 0.96 and a debt-to-equity ratio of 0.47. Boston Scientific Corporation has a 1-year low of $85.98 and a 1-year high of $109.50. The firm has a market capitalization of $141.82 billion, a price-to-earnings ratio of 51.16, a P/E/G ratio of 1.73 and a beta of 0.67.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The firm had revenue of $5.07 billion during the quarter, compared to analyst estimates of $4.97 billion. During the same period last year, the company earned $0.63 earnings per share. The business’s revenue for the quarter was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. On average, analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Insider Buying and Selling at Boston Scientific

In other news, EVP Arthur C. Butcher sold 17,313 shares of the company’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the sale, the executive vice president directly owned 23,600 shares in the company, valued at $2,396,580. This represents a 42.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the completion of the sale, the executive vice president directly owned 178,342 shares in the company, valued at approximately $17,739,678.74. The trade was a 21.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 93,095 shares of company stock valued at $9,305,450 in the last quarter. 0.50% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on BSX shares. Canaccord Genuity Group lowered their target price on Boston Scientific from $132.00 to $131.00 and set a “buy” rating on the stock in a research note on Wednesday, December 17th. Morgan Stanley lifted their price objective on shares of Boston Scientific from $125.00 to $130.00 and gave the stock an “overweight” rating in a research report on Thursday, October 23rd. Wall Street Zen downgraded shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, December 20th. Needham & Company LLC restated a “buy” rating and set a $121.00 price target on shares of Boston Scientific in a research note on Friday, October 17th. Finally, BTIG Research reiterated a “buy” rating and issued a $132.00 price objective on shares of Boston Scientific in a research note on Friday, November 21st. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, Boston Scientific presently has a consensus rating of “Buy” and an average target price of $125.21.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.